

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/009,802	01/20/1998	SEAN MCCARTHY	MEI-008-1	7895
759	90 07/30/2003			
MILLENNIUM BIOTHERAPEUTICS, INC. 620 MEMORIAL DRIVE			EXAMINER	
CAMBRIDGE, MA 02139			GUZO, DAVID	
			ART UNIT	PAPER NUMBER
			1636	31
			DATE MAILED: 07/30/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
	Advisory Action	09/009,802	MCCARTHY, SEAN				
		Examiner	Art Unit				
	(	David Guzo	1636				
Th MAILING DATE of this communication appears on the cover sheet with the correspondence addres							
	THE REPLY FILED 09 July 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.						
	PERIOD FOR REPLY [check either a) or b)]  a)  The period for reply expires 3 months from the mailing date of the final rejection.						
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.  ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).							
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timel filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.							
2. The proposed amendment(s) will not be entered because:							
(a) they raise new issues that would require further consideration and/or search (see NOTE below);							
	(b) they raise the issue of new matter (see Note below);						
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or							
<ul><li>(d)  they present additional claims without canceling a corresponding number of finally rejected claims.</li><li>NOTE:</li></ul>							
3. Applicant's reply has overcome the following rejection(s):							
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).							
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.							
	6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.						
	7. For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.						
	The status of the claim(s) is (or will be) as follows:						
	Claim(s) allowed:						
	Claim(s) objected to:						
	Claim(s) rejected: 61-88.						
	Claim(s) withdrawn from consideration:						
	8. The proposed drawing correction filed on is a) approved or b) disapproved by the Examiner.						
	9. Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s).						
1	10. ☑ Other: See Continuation Sheet						
	PRIMARY EXAMINER						
			•				

Continuation of 5. does NOT place the application in condition for allowance because: Applicants have not presented new or sufficiently convincing arguments which would overcome the outstanding rejections. Applicants' primary argument appears to be that utility for the claimed molecule may be derived from belonging to a broad class of molecules (CRSP proteins) which have a well established utility. However, in the instant case, the specific biological functions of most, if not all, mammalian members of the CRSP family have not been elucidated. Applicants also present no evidence of the specific biological activities of the claimed molecule and base their assertions of activity purely upon homology to a group of proteins which likewise are poorly understood with regard to specific biological activities.

Continuation of 10. Other: Applicants' amendment to the specification to fill in or remove blanks has been entered.